New boosted PIs should be used with T-20 for maximum impact, say new US guidelines

This article is more than 19 years old. Click here for more recent articles on this topic

HIV-positive people with multi-class drug experience should be treated with the aim of suppressing viral load below detectable levels, the revised US treatment guidelines published last week emphasise. To do this, patients should seriously consider using a boosted protease inhibitor such as tipranavir/ritonavir in combination with enfuvirtide (T-20, Fuzeon) in order to maximise the chances of virologic suppression.

The guidelines state: “The goal of treatment for patients with prior drug exposure and drug resistance is to re-establish maximal virologic suppression. Adding a drug with activity against drug-resistant virus (e.g. a potent ritonavir-boosted PI) and a drug with a new mechanism of action (e.g. HIV entry inhibitor) to an optimized background antiretroviral regimen can provide significant antiretroviral activity”.

“These guidelines clearly set more ambitious goals for the management of treatment-experienced patients now that we have potent therapies such as the combination of tipranavir and enfuvirtide,” commented Dr Anton Pozniak, Chelsea and Westminster Hospital, London.

Glossary

boosting agent

Booster drugs are used to ‘boost’ the effects of protease inhibitors and some other antiretrovirals. Adding a small dose of a booster drug to an antiretroviral makes the liver break down the primary drug more slowly, which means that it stays in the body for longer times or at higher levels. Without the boosting agent, the prescribed dose of the primary drug would be ineffective.

treatment-experienced

A person who has previously taken treatment for a condition. Treatment-experienced people may have taken several different regimens before and may have a strain of HIV that is resistant to multiple drug classes.

virological suppression

Halting of the function or replication of a virus. In HIV, optimal viral suppression is measured as the reduction of viral load (HIV RNA) to undetectable levels and is the goal of antiretroviral therapy.

optimised background therapy

When a new drug is added to a failing HIV regimen, the other drugs in the regimen (the 'background therapy') may also be changed. Any changes are based on a person’s resistance test results and treatment history. Optimised background therapy gives a new HIV regimen (or an experimental HIV drug being studied in a clinical trial) the best chance of succeeding. 

entry inhibitors

A group of antiretroviral medications that block HIV from entering a host CD4 cell. Includes both CCR5 inhibitors and fusion inhibitors.

At a symposium on Current Controversies in HIV Management hosted by NAM in June 2005, Dr Cal Cohen said: “The paucity of new drugs over the next few years needs to be appreciated by our field and the use of a new class is critical to your chances of suppression, so until integrase and maturation inhibitors come along, it’s got to be a discussion about making the best use of what’s available.”

Highlighting the impact of using enfuvirtide with a boosted protease inhibitor, Professor Richard Haubrich of the University of California, San Diego, presented an analysis of three data sets at the IDSA meeting in San Francisco earlier this month showing that the addition of enfuvirtide to a new boosted protease inhibitor increased the chances of a virologic response three-fold.

In the case of lopinavir/ritonavir and TMC-114, the addition of enfuvirtide increased the chances of achieving a viral load below 50 copies more than three-fold, whilst the addition of enfuvirtide to tipranavir/ritonavir increased the chance of viral suppression below 400 copies by 2.7-fold. The overall odds of a viral load below the limits of quantification when adding enfuvirtide to a new boosted protease inhibitor were 3.2 (95% confidence interval 2.4 – 4.2).

However the authors caution that the differences in odds ratios between boosted protease inhibitors shouldn’t be used for the purposes of comparison, since each study had slightly different entry criteria.

“These results suggest that optimal antiviral responses are achieved when a boosted protease inhibitor and enfuvirtide are initiated simultaneously.”

References

Haubrich R et al. Improved virologic response in three-class experienced patients when an active boosted protease inhibitor is combined with enfuvirtide (ENF). 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, abstract 785, 2005.